HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, included participation from key stakeholders such as ClearCardio, company leadership, and institutional investors. The company intends to use the funds to commercialize its FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection technologies, expand artificial intelligence capabilities, and for general corporate purposes.
The offering underscores HeartBeam's progress in advancing its platform technology, which is designed to be the first cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing them into a standard 12-lead ECG. This technology aims to enable portable devices that can be used wherever the patient is, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025.
The successful capital raise comes at a critical time as HeartBeam seeks to redefine cardiac health management through its innovative approach. With over 20 issued patents related to technology enablement, the company is positioning itself to address the growing need for remote cardiac monitoring solutions. The funding will support the rollout of its FDA-cleared system, which could potentially reduce healthcare costs and improve patient outcomes by enabling early detection and intervention. The extended-wear patch and heart attack detection technologies under development represent additional avenues for growth in the cardiac diagnostics market.
Investors can find the latest news and updates regarding HeartBeam in the company's newsroom at https://ibn.fm/BEAT. The full press release detailing the offering is available at https://ibn.fm/9iNYY. For more information on the cleared indications for use of HeartBeam's technology, refer to the company's website at https://www.heartbeam.com/indications.
HeartBeam's achievement in closing this public offering not only provides the necessary capital to advance its commercialization efforts but also signals investor confidence in its technology. The company's focus on creating actionable heart intelligence through portable, cable-free devices aligns with the broader trend toward decentralized healthcare and remote patient monitoring. As HeartBeam moves forward, the implications of its technology could extend beyond arrhythmia assessment to include comprehensive cardiac care management, potentially impacting how heart conditions are detected and treated globally.
